Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS)

被引：0

作者：

Symeonidis, Argiris ^{[1
]}

Diamantopoulos, Panagiotis ^{[2
]}

Galanopoulos, Athanasios ^{[3
]}

Kourakli, Alexandra ^{[1
]}

Sazakli, Eleni ^{[4
]}

Hatzimichael, Eleftheria ^{[5
]}

Pagoni, Maria ^{[6
]}

Zikos, Panagiotis ^{[7
]}

Vassilakopoulos, Theodoros P. ^{[8
]}

Gavrilaki, Eleni ^{[9
]}

Bouchla, Anthi ^{[10
]}

Kioumi, Anna ^{[11
]}

Palla, Katerina ^{[12
]}

Kotsianidis, Ioannis ^{[13
]}

Michali, Evridiki ^{[3
]}

Kartassis, Zafiris ^{[14
]}

Katodritou, Eirini ^{[15
]}

Lazaris, Vasileios ^{[1
]}

Vagia, Maria ^{[6
]}

Xanthopoulidis, George ^{[16
]}

Assimakopoulou, Theodora ^{[17
]}

Pontikoglou, Charalampos ^{[18
]}

Dimou, Maria ^{[19
]}

Dalekou-Tsolakou, Maria ^{[20
]}

Liapi, Dimitra ^{[21
]}

Kotsopoulou, Maria ^{[22
]}

Labropoulou, Vassiliki ^{[1
]}

Papoutselis, Menelaos ^{[13
]}

Barmparousi, Despina ^{[23
]}

Vlachaki, Efthymia ^{[24
]}

Kaiafa, Georgia ^{[25
]}

Chandrinou, Eleni ^{[26
]}

Karmas, Panagiotis ^{[27
]}

Terpos, Evangelos ^{[28
]}

Vassilopoulos, George ^{[29
]}

Panayiotidis, Panayiotis ^{[19
]}

Viniou, Nora-Athina ^{[2
]}

Pappa, Vassiliki ^{[10
]}

机构：

[1] Univ Patras, Dept Internal Med, Hematol Div, Patras 26504, Greece

[2] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Internal Med 1, Athens 11527, Greece

[3] G Gennimatas Gen Hosp, Dept Hematol, Athens 11527, Greece

[4] Univ Patras, Med Sch, Lab Publ Hlth, Patras 26504, Greece

[5] Univ Ioannina, Sch Med, Dept Hematol, Ioannina 45110, Greece

[6] Evangelismos Med Ctr, Hematol Lymphoma Dept, BMT Unit, Athens 10676, Greece

[7] St Andreas Gen Hosp, Dept Hematol, Patras 26332, Greece

[8] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Hematol, Athens 11527, Greece

[9] G Papanicolaou Gen Hosp Thessaloniki, Dept Hematol & Stem Cell Transplantat, Exochi 57010, Greece

[10] Univ Gen Hosp Attikon, Dept Internal Med 2, Athens 12462, Greece

[11] Papageorgiou Hosp, Dept Hematol, Thessaloniki 54624, Greece

[12] Gen Hosp Chania, Dept Hematol, Khania 73300, Greece

[13] Democritus Univ Thrace, Med Sch, Dept Hematol, Alexandroupolis 68100, Greece

[14] Gen Hosp Halkida, Hematol Unit, Halkida 34100, Greece

[15] Theagene Hosp, Dept Hematol, Thessaloniki 54639, Greece

[16] Gen Hosp Xanthi, Dept Hematol, Xanthi 67100, Greece

[17] Sismanogle Hosp, Dept Hematol, Athens 15126, Greece

[18] Univ Crete, Med Sch, Dept Hematol, Iraklion 71003, Greece

[19] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Propedeut Dept Internal Med 1, Athens 11527, Greece

[20] Gen Hosp Kalamata, Hematol & Thalassemia Unit, Antikalamos 24100, Greece

[21] Venizele Hosp, Dept Hematol, Iraklion 71409, Greece

[22] Metaxa Anticanc Hosp, Dept Hematol, Piraeu 18537, Greece

[23] Alexandra Gen Hosp, Dept Hematol, Athens 11528, Greece

[24] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Internal Med 2, Thessaloniki 54124, Greece

[25] AHEPA Univ Hosp, Propedeut Dept Internal Med 1, Thessaloniki 54636, Greece

[26] Athens Med Ctr, Dept Hematol, Athens 15125, Greece

[27] Army Share Fund Hosp NIMTS, Dept Hematol, Athens 11524, Greece

[28] Natl & Kapodistrian Univ Athens, Alexandra Hosp, Sch Med, Dept Clin Therapeut, Athens 10679, Greece

[29] Univ Thessaly, Sch Med, Dept Hematol, Larisa 41334, Greece

来源：

CANCERS | 2025年 / 17卷 / 09期

关键词：

myelodysplastic syndromes; del(5)q; lenalidomide; treatment; real-world-data; prognosis; PROGNOSTIC SCORING SYSTEM; ACUTE MYELOID-LEUKEMIA; TRANSFUSION-DEPENDENT PATIENTS; INTERNATIONAL WORKING GROUP; CHROMOSOME; 5Q; AML PROGRESSION; RISK; DEL(5Q); DELETION; THERAPY;

D O I：

10.3390/cancers17091388

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background-Objectives: Although considered standard of care for patients with low-/intermediate-1 risk MDS and isolated del(5q), lenalidomide is not widely used in patients exhibiting additional cytogenetic abnormalities, on top of del(5)q. The aim of this study was to provide real-world evidence for the efficacy of lenalidomide in patients with del(5q), with or without additional cytogenetic abnormalities. Methods: Patients with MDS exhibiting del(5q) in the Greek National Myelodysplastic Syndromes Registry were analyzed if they had received at least one lenalidomide dose and detailed response assessment/follow-up was available. Results: Among 238 patients analyzed, 153 (64.3%) had del(5q) syndrome (Group-I), 34 (14.3%) had an isolated del(5q) abnormality but were not 5q- syndrome (Group-II), 26 (10.9%) had del(5q) plus only one additional cytogenetic abnormality (Group-III), and 25 (10.5%) had del(5q) plus >1 additional abnormality (Group-IV). Among 218 (91.6%) evaluable patients, a major response was achieved by 146 (67.0%) patients, 114/146 (78.1%) in Group-I, 18/31 (58.1%) in Group-II, 10/20 (50.0%) in Group-III, and 4/21 (19.0%) in Group-IV. Overall, hematological response was seen in 177/218 (81.2%) patients, even among those with an excess of bone marrow blasts/frank acute myeloid leukemia. Duration of response was comparable between the four patient groups. A complete cytogenetic response was achieved by 38.0% overall, more commonly in Group-I (42.3%) and -III (35.7%). Transfusion-independent patients and those with a higher MCV or lower marrow blast cells at baseline had a higher probability of achieving a major response. With multivariate analysis, factors associated with overall survival were age, performance status, transfusion dependence, and marrow blast cell percentage at treatment start, as well as time from initial diagnosis to lenalidomide start. Conclusions: Lenalidomide was highly effective in patients with the del(5)q syndrome and also in those with isolated del(5)q, other than del(5)q syndrome, or those exhibiting del(5)q plus only one additional cytogenetic abnormality, not affecting chromosome 7.

引用

页数：23

共 67 条

[1] Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program [J].

Abouyahya, Imane ;

Alhan, Canan ;

Westers, Theresia M. ;

te Boekhorst, Peter A. ;

Kappers-Klunne, Mies C. ;

Coenen, Jules L. ;

Heyning, Fenna H. ;

Huls, Gerwin A. ;

de Wolf, Joost T. ;

Imholz, Alex L. ;

Koene, Harry R. ;

Veth, Gerda ;

de Kruijf, Evert-Jan F. M. ;

Muus, Petra ;

Planken, Erwin V. ;

Segeren, Christine M. ;

Vasmel, Wies L. ;

van der Velden, Ankie M. ;

Velders, Gerjo A. ;

Koedam, Jan ;

Ossenkoppele, Gert J. ;

van de Loosdrecht, Arjan A. .

LEUKEMIA & LYMPHOMA, 2013, 54 (04) :874-877

[2] What lies beyond del(5q) in myelodysplastic syndrome? [J].

Adema, Vera ;

Bejar, Rafael .

HAEMATOLOGICA, 2013, 98 (12) :1819-1821

[3] Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies [J].

Ades, Lionel ;

Le Bras, Fabien ;

Sebert, Marie ;

Kelaidi, Charikleia ;

Lamy, Thierry ;

Dreyfus, Francois ;

Eclache, Virginie ;

Delaunay, Jacques ;

Bouscary, Didier ;

Visanica, Sorin ;

Turlure, Pascal ;

Bresler, Agnes Guerci ;

Cabrol, Marie-Paule ;

Banos, Anne ;

Blanc, Michel ;

Vey, Norbert ;

Delmer, Alain ;

Wattel, Eric ;

Chevret, Sylvie ;

Fenaux, Pierre .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (02) :213-218

[4] Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study [J].

Ades, Lionel ;

Boehrer, Simone ;

Prebet, Thomas ;

Beyne-Rauzy, Odile ;

Legros, Laurence ;

Ravoet, Christophe ;

Dreyfus, Francois ;

Stamatoullas, Aspasia ;

Chaury, Marie Pierre ;

Delaunay, Jacques ;

Laurent, Guy ;

Vey, Norbert ;

Burcheri, Sara ;

Mbida, Rose-Marie ;

Hoarau, Natacha ;

Gardin, Claude ;

Fenaux, Pierre .

BLOOD, 2009, 113 (17) :3947-3952

[5] Complete Remission of del(5q) Myelodysplastic Syndrome after 7 Days of Lenalidomide Therapy Gives an Alert! [J].

Al-Jafar, Hassan A. ;

Al-Azmi, Salih ;

Qassem, J. A. ;

Hasan, Eman A. ;

Alduaij, Arwa .

CASE REPORTS IN ONCOLOGY, 2012, 5 (03) :586-591

[6] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[7] Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency [J].

Arcioni, Francesco ;

Roncadori, Andrea ;

Di Battista, Valeria ;

Tura, Sante ;

Covezzoli, Anna ;

Cundari, Sante ;

Mecucci, Cristina .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (01) :78-85

[8]

Aschauer Gregor, 2015, Clin Lymphoma Myeloma Leuk, V15, pe143, DOI 10.1016/j.clml.2015.07.645

[9] Age, Blasts, Performance Status and Lenalidomide Therapy Influence the Outcome of Myelodysplastic Syndrome With Isolated Del(5q): A Study of 58 South American Patients [J].

Azevedo, R. S. ;

Belli, C. ;

Bassolli, L. ;

Ferri, L. ;

Perusini, M. A. ;

Enrico, A. ;

Pereira, T. D. M. ;

Junior, W. F. S. ;

Buccheri, V ;

Pinheiro, R. F. ;

Magalhaes, S. M. ;

Schuster, S. ;

Castelli, J. B. ;

Traina, F. ;

Rocha, V ;

Velloso, E. D. R. P. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (01) :E1-E6

[10] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q) [J].

Butrym, Aleksandra ;

Lech-Maranda, Ewa ;

Patkowska, Elzbieta ;

Kumiega, Beata ;

Bieniaszewska, Maria ;

Mital, Andrzej ;

Madry, Krzysztof ;

Torosian, Tigran ;

Wichary, Ryszard ;

Rybka, Justyna ;

Warzocha, Krzysztof ;

Mazur, Grzegorz .

BMC CANCER, 2015, 15

← 1 2 3 4 5 6 7 →